Myelodysplastic Myeloproliferative Neoplasms

• CLINICAL_TRIALS withdrawal · 2026-02-13
  Clinical Trial Update: Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating the combination of decitabine, cedazuridine (ASTX727), and ASTX029 (an ERK inhibitor) for patients wit…

• CLINICAL_TRIALS withdrawal · 2015-06-08
  Clinical Trial Update: Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment [Phase 1]

  Phase 1 trial evaluating total marrow and total lymph node irradiation with fludarabine and melphalan followed by donor stem cell transplant…

• CLINICAL_TRIALS withdrawal · 2015-05-29
  Clinical Trial Update: Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

  A clinical trial evaluating perceived burden in late-stage cancer patients and their caregivers has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2013-02-15
  Clinical Trial Update: Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies [Phase 1, Phase 2]

  Clinical trial update notes the withdrawal of a Phase 1/2 study evaluating antimicrobial versus saline solutions to maintain catheter patenc…

• CLINICAL_TRIALS withdrawal · 2012-10-02
  Clinical Trial Update: Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer [Phase 2]

  Phase 2 study of busulfan and fludarabine conditioning before donor stem cell transplant for hematologic cancers has been withdrawn.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.